at baseline, 69% had diabetes, 5.8% had glomerular disease and 25% had other forms of CKD. The average baseline UACR in the patients with glomerular disease was 1,311 mg/g (148 mg/mmol) and very few patients had nephrotic-range albuminuria (UACR ≥3,000 mg/g (≥340 mg/mmol)) owing to non-diabetic glomerular disease.
After an average follow-up of 3.4 years, 3,935 patients (13%) reached a composite end point of doubling of serum creatinine levels or ESRD. For each 30% decline in UACR from baseline over 6 months of observation, the incidence of ESRD declined by 27%. Interventions that resulted in a decrease in UACR of ≥30% relative to baseline (that is, those that decreased the geometric mean UACR to ≥0.7 of baseline values) were associated with a HR for the composite end point of 0.68 (95% CI 0.47-0.95). The study was underpowered to assess the impact of the aetiology of kidney disease on outcomes.
Taken together, these meta-analyses provide considerable impetus to consider a percentage decline of UACR (or urine proteinto-creatinine ratio) from baseline of ~30% over 6-24 months as a surrogate outcome measure of avoidance of future development of ESRD or doubling of serum creatinine levels in clinical trials of interventions in proteinuric kidney disease. The authors of and participants in these analyses deserve much gratitude for their monumental efforts. An earlier attempt to validate an early change in proteinuria as a surrogate outcome measure was only partially successful owing to limitations of statistical power and a narrow spectrum of interventions 8 . The current studies remedy some, but not all, of these limitations. In particular, the included cohorts are heavily weighted towards diabetic kidney disease and have limited representation of common non-diabetic glomerular diseases.
Candidate surrogate outcome measures identified by meta-analyses of large databases encompassing diverse kidney diseases and interventions are unlikely to be useful for the design and execution of interventional trials of novel agents or repurposing of approved agents. Such trials generally focus on single or related diseases. The lack of representation of patients with nephrotic syndrome and non-diabetic glomerular disease in the recent meta-analyses limits their generalizability to a broad swath of glomerular diseases and interventions. Nevertheless, examination of early but durable changes in proteinuria (or albuminuria) as a surrogate for 'hard' outcomes (such as doubling of serum creatinine or ESRD) in specific diseases, such as diabetic nephropathy and IgA nephropathy, has been quite rewarding 9 . Importantly, the relationship between time-averaged proteinuria and glomerular filtration rate decline is not uniform among primary glomerular diseases. This relationship tends to be linear in IgA nephropathy but threshold-based in other diseases such as focal segmental glomerulosclerosis and membranous nephropathy, and it may also be influenced by gender 10 . Whether a certain percentage change in proteinuria from baseline is an efficient surrogate at all levels of proteinuria remains uncertain. Does a 30% decline in proteinuria over 6-24 months from 10 g to 7 g per day translate to an equal protection from ESRD as a 30% decrease from 1.0 g per day to 0.7 g per day?
What is the impact of residual proteinuria and the durability of the effect of an intervention on proteinuria? To what extent are the effects of an early change in proteinuria (or albuminuria) as a surrogate for subsequent risk of ESRD dependent on the specific disease being examined or the intervention used? These crucial questions cannot be answered by the meta-analyses conducted to date. Nonetheless, the recent studies move the field forward in a very important way and set the stage for more granular studies in the future. Much more work is needed. In my opinion, the case for an early change in proteinuria (or albuminuria) as a broad all-inclusive surrogate measure for hard outcomes in kidney disease is not yet closed. 
Modelling diabetic vasculopathy with human vessel organoids

Ryuji Morizane
A new study reports that human blood vessel organoids can be generated through the directed differentiation of human pluripotent stem cells. Use of these blood vessel organoids to model diabetic vasculopathy led to the identification of a new potential therapeutic target, suggesting that this system could have translational value for studies of diabetes complications. Diabetic kidney disease (DKD) is one of the most common and devastating complications of diabetes, for which limited treatments exist. The use of organoids to study DKD has been limited by the finding that kidney organoids show limited vascularization in vitro. The formation of vasculature networks in kidney organoids is enhanced following their transplantation into mice, and, similarly to the findings by Wimmer et al. 5 , the vasculature of human kidney organoids connects to the mouse vasculature following transplantation 7 . However, xenogeneic vascularized organoids might not fully recapitulate the pathophysiology of DKD in humans. In addition, protocols that require animal transplantation limit the scalability of these studies. To overcome these issues, an in vitro approach has been developed whereby vascularization of whole kidney organoids can be achieved in vitro by exposing organoids within engineered chips to a fluidic environment 8 . In addition to inducing vascularization, exposure to flow enhanced the maturation of nephron epithelial cells in these organoids, suggesting that culture systems that better mimic the in vivo environment may provide better platforms for modelling kidney and vascular development and for the study of diabetic complications in human cells. Multi-organ-on-a-chip approaches involving combinations of vascularized kidney and blood vessel organoids might provide a useful in vitro system to study interorgan communication in diabetic conditions.
Although organoids have the potential to be highly valuable for the study of development embryonic stem cells (ESCs) and induced PSCs (iPSCs) 1 . The first organoid culture system was established using intestinal stem cells using culture conditions that mimicked the in vivo environment 2 . Since then, protocols involving the sequential application of growth factors and signals at specific combinations and concentrations have been developed to enable the directed differentiation of stem cells into organoids representative of various organs including the intestine, liver, lung, brain, pancreas, stomach and kidneys 3, 4 . Now, Wimmer et al. 5 describe the directed differentiation of human PSCs into blood vessel organoids and show that these organoids can be used to model diabetic vasculopathy.
The in vitro differentiation of stem cells into vascular endothelial and mural cells was first reported almost 20 years ago 6 . At that time, a stochastic differentiation approach was used to generate vascular endothelial growth factor receptor 2 (VEGFR2) + E-cadherin − vascular progenitor cells from mouse ESCs. Following a purification step using flow cytometry sorting, these cells were differentiated into endothelial and mural cells in a 3D culture system using collagen gels. Wimmer et al. now show that human blood vessel organoids can be generated from human ESCs and iPSCs through directed differentiation without the need for cell sorting during the differentiation process 5 . Treatment of stem cell aggregates in suspension culture with the glycogen synthase kinase 3 (GSK3) inhibitor CHIR99021 to activate WNT signalling promoted mesoderm lineage diffe rentiation. Vascular lineage induction was then achieved by modulating bone morphogenetic protein (BMP), vascular endothelial growth factor A (VEGFA) and fibroblast growth factor 2 (FGF2) levels. Cell aggregates were subsequently embedded in a mixed matrigel-collagen I gel to facilitate the formation of a vascular network. At around day 18 of differentiation, individual cell aggregates were extracted from the gels and further differentiated with fetal bovine serum, VEGFA and FGF2 in suspension culture (Fig. 1) Perhaps the most interesting aspect of this new study is the use of these vessel organoids to model diabetic vasculopathy 5 . The researchers show that culturing the vessel organoids in high-glucose media for up to 3 weeks induces thickening of vascular basement membranes -a key feature of diabetic microvasculopathy. Addition of the pro-inflammatory cytokines tumour necrosis factor (TNF) and IL-6 to the media further enhanced this thickening. Moreover, human vessel organoids transplanted into mice with streptozotocin-induced diabetes exhibited similar features to those of organoids cultured under high-glucose conditions, with thickening of the basement membrane, vessel regression and loss of endothelial cells. Last, the researchers used a drug screening approach to identify delta-like protein 4 (DLL4)-NOTCH3 signalling as a driver of this process and showed that inhibition of NOTCH3 alleviated the microvascular pathologies in transplanted mice.
Microvasculopathy is a major complication of diabetes mellitus and can eventually lead to blindness, kidney failure, cardiovascular
The ability to recapitulate microvasculopathy in human vessel organoids will provide valuable opportunities and disease, the reproducibility of protocols is a major challenge. For example, a 2018 study reported poor interlaboratory reproducibility of gene expression signatures in iPSC-derived neurons generated using a well-defined differentiation protocol 9 . A more recent study used single-cell RNA sequencing to demonstrate interexperimental and interclonal variation in the differentiation of kidney organoids within the same laboratory 10 . Quality control is necessary for organoids to be reproducibly generated; however, markers and methods that enable such reproducibility have not been well defined. In fact, quantitative quality control steps, such as analyses of progenitor marker expression during the process of directed differentiation, were not clearly described by Wimmer et al. 5 . Detailed protocols with descriptions of appropriate quality control measures, such as marker expression analyses at each step of directed differentiation, are needed for researchers to reliably reproduce protocols for organoid generation.
In summary, Wimmer et al. demonstrate that human blood vessel organoids can be generated from human PSCs by directed differentiation and show that these organoids can be used to model diabetic vasculopathy and identify potential therapeutic targets. Many challenges remain in using such systems for the study of diabetic vasculopathies, including the limited in vitro vascularization of organoid systems such as kidney organoids as well as reproducibility issues, but this study helps move the field forward by providing an additional tool with which to study diabetic complications in human vascular tissues. As ESA therapy is expensive and i.v. iron products are inexpensive, maintaining high iron stores (reflected by high ferritin levels) using i.v. iron is a popular approach for the treatment of anaemia. However, i.v. iron has never undergone large, long-term safety trials. Nephrology guidelines and some experts have cautioned that i.v. iron may be unsafe so should only be used to maintain ferritin levels >200 ng/ml and should be avoided when ferritin exceeds 500 ng/ml (ReFs
). Ironically, this recommendation first appeared in 2006, when the KDOQI guidelines raised the haemoglobin target after dismissing concerns regarding the safety of ESAs [4] [5] [6] . Now, the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial reports that proactive i.v. iron administration is safe and improves clinical outcomes in these patients 7 .
Concerns about i.v. iron therapy in patients on dialysis date back to at least 1998, when the Normal Haematocrit Trial reported a trend towards increased deaths in patients on haemodialysis who were given high-dose epoetin to normalize haematocrit levels (target of 42%) in comparison with those who received lower doses of epoetin to maintain haematocrit levels at 30% 5, 8 . A post hoc analysis of these data reported a correlation between i.v. iron dose and death 5 . During the trial, however, the higher haematocrit target group had lower mean ferritin levels than the lower target group, possibly leading to higher ESA dose exposure in the former group. Was the harm a result of too much i.v. iron or of high ESA doses due in part to iron deficiency?
The PIVOTAL trial tested the safety and efficacy of i.v. iron by randomly assigning 2,141 patients in their first year on haemodialysis to either a reactive strategy of relatively small doses of i.v. iron when ferritin was <200 ng/ml or TSAT was <20% or a proactive strategy of a 600 mg iron load in month 1 followed by 400 mg monthly when ferritin was <700 ng/ml and TSAT was <40% The PIVOTAL trial shows that proactive intravenous (i.v.) iron administration reduces cardiovascular events and deaths, transfusions and erythropoiesisstimulating agent doses and does not increase infections in patients on haemodialysis. These findings upend the warnings of guidelines and experts about the dangers of i.v. iron and prove that maintaining low iron stores is harmful.
